Table 3 Clinicopathologic characteristics of 1184 cases of lymph node negative ER+/HER2- breast cancer with RS < 18, treated with endocrine therapy only (all percentages within columns)
|  | RS 0–10 (n = 462) | RS 11–17 (n = 722) | Total (n = 1184) |
|---|---|---|---|
RS: Mean, median (range) | 7, 8 (0–10) | 14, 14 (11–17) | 11, 12 (0–17) |
Age at diagnosis | |||
 Mean, median (range); years | 58, 59 (25–84) | 58, 57 (22–90) | 58, 58 (22–90) |
  < 40 years; n (%) | 19 (4.1%) | 21 (2.9%) | 40 (3.4%) |
  40–49 years; n (%) | 98 (21.2%) | 156 (21.6%) | 254 (21.5%) |
  ≥ 50 years; n (%) | 345 (74.7%) | 545 (75.5%) | 890 (75.2%) |
Tumor size, median (range); cm | 1.28, 1.1 (0.35–5.5) | 1.28, 1.1 (0.3–4.5) | 1.28, 1.1 (0.3–5.5) |
Multifocality; n (%) | 106 (22.9%) | 128 (17.7%) | 234 (19.8%) |
LVI; n (%) | 72 (15.6%) | 126 (17.5%) | 198 (16.7%) |
Local treatment; n (%) | |||
 BCS only | 12 (2.6%) | 28 (3.9%) | 40 (3.4%) |
 BCS and radiation therapy | 301 (65.2%) | 515 (71.3%) | 816 (68.9%) |
 Total mastectomy | 149 (32.3%) | 177 (24.5%) | 326 (27.5%) |
 Total mastectomy and radiation therapy | 0 | 2 (0.3%) | 2 (0.2%) |
LRR; n (%) | 3 (0.6%) | 5 (0.7%) | 8 (0.7%) |
Median follow-up (range); months | 51.7 (0.9–108.3) | 51.3 (1–93) | 51.4 (0.9–108.3) |